BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28696693)

  • 1. Synthesis and Evaluation of Agelastatin Derivatives as Potent Modulators for Cancer Invasion and Metastasis.
    Antropow AH; Xu K; Buchsbaum RJ; Movassaghi M
    J Org Chem; 2017 Aug; 82(15):7720-7731. PubMed ID: 28696693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe.
    Jouanneau M; McClary B; Reyes JC; Chen R; Chen Y; Plunkett W; Cheng X; Milinichik AZ; Albone EF; Liu JO; Romo D
    Bioorg Med Chem Lett; 2016 Apr; 26(8):2092-7. PubMed ID: 26951751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and anticancer activity of all known (-)-agelastatin alkaloids.
    Han S; Siegel DS; Morrison KC; Hergenrother PJ; Movassaghi M
    J Org Chem; 2013 Dec; 78(23):11970-84. PubMed ID: 24152243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
    Stout EP; Choi MY; Castro JE; Molinski TF
    J Med Chem; 2014 Jun; 57(12):5085-93. PubMed ID: 24673739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total synthesis of (+/-)-agelastatin A, a potent inhibitor of osteopontin-mediated neoplastic transformations.
    Dickson DP; Wardrop DJ
    Org Lett; 2009 Mar; 11(6):1341-4. PubMed ID: 19228041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The
    D'Ambrosio M
    Molecules; 2023 Sep; 28(19):. PubMed ID: 37836663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New total synthesis of the marine antitumor alkaloid (-)-agelastatin A.
    Domostoj MM; Irving E; Scheinmann F; Hale KJ
    Org Lett; 2004 Jul; 6(15):2615-8. PubMed ID: 15255704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agelastatin E, agelastatin F, and benzosceptrin C from the marine sponge Agelas dendromorpha.
    Tilvi S; Moriou C; Martin MT; Gallard JF; Sorres J; Patel K; Petek S; Debitus C; Ermolenko L; Al-Mourabit A
    J Nat Prod; 2010 Apr; 73(4):720-3. PubMed ID: 20166736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation.
    Mason CK; McFarlane S; Johnston PG; Crowe P; Erwin PJ; Domostoj MM; Campbell FC; Manaviazar S; Hale KJ; El-Tanani M
    Mol Cancer Ther; 2008 Mar; 7(3):548-58. PubMed ID: 18347142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enantiospecific formal total synthesis of the tumor and GSK-3 beta inhibiting alkaloid, (-)-agelastatin A.
    Hale KJ; Domostoj MM; Tocher DA; Irving E; Scheinmann F
    Org Lett; 2003 Aug; 5(16):2927-30. PubMed ID: 12889910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isosteroidal alkaloids from Fritillaria hupehensis Hsiao et K.C.Hsia: Synthesis and biological evaluation of alkaloid derivatives as potential cytotoxic agents.
    Liu XH; Zou J; Li YJ; Liu M; He CL; Liu YR; Wang JZ; Chen DL
    Steroids; 2021 Dec; 176():108929. PubMed ID: 34653443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compounds, compositions, and methods of agelastatin alkaloids: patent evaluation of WO2015042239 (A1).
    Yoshimitsu T; Tun HW
    Expert Opin Ther Pat; 2017 Feb; 27(2):113-119. PubMed ID: 28056571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alkynyliodonium salts in organic synthesis. Development of a unified strategy for the syntheses of (-)-agelastatin A and (-)-agelastatin B.
    Feldman KS; Saunders JC; Wrobleski ML
    J Org Chem; 2002 Oct; 67(20):7096-109. PubMed ID: 12354005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total synthesis of the beta-catenin inhibitor, (-)-agelastatin A: a second-generation approach based on radical aminobromination.
    Yoshimitsu T; Ino T; Futamura N; Kamon T; Tanaka T
    Org Lett; 2009 Aug; 11(15):3402-5. PubMed ID: 19588910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A stereodivergent strategy to both product enantiomers from the same enantiomer of a stereoinducing catalyst: agelastatin A.
    Trost BM; Dong G
    Chemistry; 2009 Jul; 15(28):6910-9. PubMed ID: 19533707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total synthesis of (-)-agelastatin A.
    Yoshimitsu T; Ino T; Tanaka T
    Org Lett; 2008 Dec; 10(23):5457-60. PubMed ID: 19006318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis and in Vitro Evaluation of Tylophorine Derivatives as Possible Antitumor Agents.
    Mang Z; Zhang S; Bai J; Li M; Li H
    Chem Biodivers; 2020 Sep; 17(9):e2000066. PubMed ID: 32567792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of bengacarboline derivatives.
    Pouilhès A; Kouklovsky C; Langlois Y; Baltaze JP; Vispé S; Annereau JP; Barret JM; Kruczynski A; Bailly C
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1212-6. PubMed ID: 18083028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total Synthesis and Anti-Cancer Activity of All Known Communesin Alkaloids and Related Derivatives.
    Pompeo MM; Cheah JH; Movassaghi M
    J Am Chem Soc; 2019 Sep; 141(36):14411-14420. PubMed ID: 31422662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Eukaryotic Translation by the Antitumor Natural Product Agelastatin A.
    McClary B; Zinshteyn B; Meyer M; Jouanneau M; Pellegrino S; Yusupova G; Schuller A; Reyes JCP; Lu J; Guo Z; Ayinde S; Luo C; Dang Y; Romo D; Yusupov M; Green R; Liu JO
    Cell Chem Biol; 2017 May; 24(5):605-613.e5. PubMed ID: 28457705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.